

- classification system. Draft Guidance. Silver Spring, MD: US Food and Drug Administration, May 2015 (Revision 1).
- 28 Vinod P, *et al.* Solubility enhancement of poorly soluble drugs by using novel techniques: a review. *J Curr Pharma Res* 2014; 4(3): 1258–1270.
 - 29 Davis M, Brewster M. Cyclodextrin-based pharmaceuticals: past, present and future. *Nat Rev Drug Discov* 2004; 3(12): 1023–1035.
 - 30 Vasconcelos T, *et al.* Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. *Drug Discov Today* 2007; 12(23–24): 1068–1075.
 - 31 Remon JP, *et al.* (Co-)extrusion and injection moulding as manufacturing tools for oral solid dosage forms. *Bull Tech Gattefossé* 2012; 105: 80–104.
 - 32 Zema L, *et al.* Injection Molding and its application to drug delivery. *J Control Release* 2012; 159(3): 324–331.
 - 33 Ghebremeskel AN, *et al.* Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Selection of polymer-surfactant combinations using solubility parameters and testing the processability. *Int J Pharm* 2007; 328(2): 119–129.
 - 34 Wang W. Lyophilization and development of solid protein pharmaceuticals. *Int J Pharm* 2000; 203(1–2): 1–60.
 - 35 Jones RJ, *et al.* The influence of formulation and manufacturing process parameters on the characteristics of lyophilized orally disintegrating tablets. *Pharmaceutics* 2011; 3(3): 440–457.
 - 36 Hardwick LM, *et al.* Critical factors in the design and optimisation of lyophilisation processes. *Innov Pharm Technol* 2008; 26(70): 72–74.
 - 37 Baheti A, *et al.* Excipients used in lyophilization of small molecules. *J Excipients Food Chem* 2010; 1(1): 41–54.
 - 38 Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. *J Pharmacol Toxicol Methods* 2000; 44(1): 235–249.
 - 39 Hamman J, Steenekamp J. Excipients with specialized functions for effective drug delivery. *Expert Opin Drug Deliv* 2012; 9(2): 219–230.
 - 40 Gibson L. Lipid-based excipients for oral drug delivery. In: Hauss DJ, ed. *Oral lipid-based formulations: enhancing the bioavailability of poorly water soluble drugs*. New York: Informa Healthcare, 2007; 33–61.
 - 41 Kuentz M. Lipid-based formulations for oral delivery of lipophilic drugs. *Drug Discov Today Technol* 2012; 9(2): e97–e104.
 - 42 Lindmark T, *et al.* Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. *J Pharmacol Exp Ther* 1998; 284(1): 362–369.
 - 43 Marti-Mestres G, Nielloud F. Main surfactants used in the pharmaceutical field. In: Marti-Mestres G, Nielloud F, eds. *Pharmaceutical Emulsions and Suspensions*. New York: Marcel Dekker, 2000; 1–18.
 - 44 Joshi S, Petereit HU. Film coatings for taste masking and moisture protection. *Int J Pharm* 2013; 457(2): 395–406.
 - 45 Wise DL, ed. *Handbook of Pharmaceutical controlled release technology*. New York: Marcel Dekker; 2000.
 - 46 Mastropietro DJ, Omidian H. Prevalence and trends of celluloses in pharmaceutical dosage forms. *Drug Dev Ind Pharm* 2013; 39(2): 382–392.
 - 47 Dow Chemical Company. Product Information: using METHOCEL cellulose ethers for controlled release of drugs in hydrophilic matrix systems, July 2000. http://www.colorcon.com/literature/marketing/mr/Extended%20Release/METHOCEL/English/hydroph_matrix_-broch.pdf (accessed 14 September 2016).
 - 48 Ansel HC *et al.* *Pharmaceutical dosage forms and drug delivery systems*, 10th edn. Baltimore, MD: Lippincott Williams and Wilkins; 2014: 305–306.
 - 49 Guo X, *et al.* Ion-exchange resins as drug delivery carriers. *J Pharm Sci* 2009; 98(11): 3886–3902.
 - 50 Srikanth MV, *et al.* Ion-exchange resins as controlled drug delivery carriers. *J Sci Res* 2010; 2(10): 597–611.
 - 51 Reddy JRK, *et al.* Review on: pulsatile drug delivery systems. *J Pharm Sci Res* 2009; 1(4): 109–115.
 - 52 Krogel I, Bodmeier R. Floating or pulsatile drug delivery systems based on coated effervescent cores. *Int J Pharm* 1999; 187(2): 175–184.
 - 53 Patel GC, Patel MM. Developing a modified Pulsincap system. *Pharm Technol Eur* 2009; 21(11): 45–51.
 - 54 Jones B. Two-piece gelatin capsules: excipients for powder products, European practice. *Pharm Tech Eur* 1995; 11: 25–34.
 - 55 Patel R, Podczek F. Investigation of the effect of type and source of microcrystalline cellulose on capsule filling. *Int J Pharm* 1996; 128(1–2): 123–127.
 - 56 Digenis GA, *et al.* Crosslinking of gelatin within capsules and its relevance to their *in vitro-in vivo* performance. *J Pharm Sci* 1994; 83(7): 915–921.
 - 57 Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER). Guidance for industry: nonclinical studies for the safety evaluation of pharmaceutical excipients. Guidance for Industry. Rockville, MD: US Food and Drug Administration; May 2005.
 - 58 Hasselbach B. Public health challenges for the quality of human drugs. Presented at the FDA/Xavier University Global Outsourcing Conference. Cincinnati, OH, 2010.

Date of Revision

3 April 2017.